Akademska digitalna zbirka SLovenije - logo
E-resources
Full text
Peer reviewed Open access
  • Daprodustat for the Treatme...
    Singh, Ajay K; Carroll, Kevin; Perkovic, Vlado; Solomon, Scott; Jha, Vivekanand; Johansen, Kirsten L; Lopes, Renato D; Macdougall, Iain C; Obrador, Gregorio T; Waikar, Sushrut S; Wanner, Christoph; Wheeler, David C; Więcek, Andrzej; Blackorby, Allison; Cizman, Borut; Cobitz, Alexander R; Davies, Rich; Dole, Jo; Kler, Lata; Meadowcroft, Amy M; Zhu, Xinyi; McMurray, John J.V

    The New England journal of medicine, 12/2021, Volume: 385, Issue: 25
    Journal Article

    This trial compared the oral HIF-PHI daprodustat with conventional erythropoiesis-stimulating agents for the treatment of anemia in patients with chronic kidney disease receiving dialysis. Daprodustat was noninferior to ESAs regarding the change in the hemoglobin level from baseline and cardiovascular outcomes.